BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17311611)

  • 1. New molecular targets for hepatocellular carcinoma: the ErbB1 signaling system.
    Berasain C; Castillo J; Prieto J; Avila MA
    Liver Int; 2007 Mar; 27(2):174-85. PubMed ID: 17311611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The epidermal growth factor receptor: a link between inflammation and liver cancer.
    Berasain C; Perugorria MJ; Latasa MU; Castillo J; Goñi S; Santamaría M; Prieto J; Avila MA
    Exp Biol Med (Maywood); 2009 Jul; 234(7):713-25. PubMed ID: 19429859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New therapies for hepatocellular carcinoma.
    Avila MA; Berasain C; Sangro B; Prieto J
    Oncogene; 2006 Jun; 25(27):3866-84. PubMed ID: 16799628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclooxygenase-2 in hepatocellular carcinoma.
    Wu T
    Cancer Treat Rev; 2006 Feb; 32(1):28-44. PubMed ID: 16337744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now.
    Pang RW; Poon RT
    Oncology; 2007; 72 Suppl 1():30-44. PubMed ID: 18087180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted therapy of hepatocellular cancer.
    Wysocki PJ
    Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options for hepatocellular carcinoma.
    Sandhu DS; Tharayil VS; Lai JP; Roberts LR
    Expert Rev Gastroenterol Hepatol; 2008 Feb; 2(1):81-92. PubMed ID: 19072372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis of hepatocellular carcinoma and molecular therapies.
    Mínguez B; Tovar V; Chiang D; Villanueva A; Llovet JM
    Curr Opin Gastroenterol; 2009 May; 25(3):186-94. PubMed ID: 19387255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of hepatocellular carcinoma.
    Aravalli RN; Steer CJ; Cressman EN
    Hepatology; 2008 Dec; 48(6):2047-63. PubMed ID: 19003900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategy and mechanism for the prevention of hepatocellular carcinoma: phosphorylated retinoid X receptor alpha is a critical target for hepatocellular carcinoma chemoprevention.
    Shimizu M; Takai K; Moriwaki H
    Cancer Sci; 2009 Mar; 100(3):369-74. PubMed ID: 19068086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation and liver cancer: new molecular links .
    Berasain C; Castillo J; Perugorria MJ; Latasa MU; Prieto J; Avila MA
    Ann N Y Acad Sci; 2009 Feb; 1155():206-21. PubMed ID: 19250206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapies in hepatocellular carcinoma.
    Wörns MA; Weinmann A; Schuchmann M; Galle PR
    Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin-mediated hepatocellular carcinoma cell migration: cooperative action via proteinase-activated receptors 1 and 4.
    Kaufmann R; Rahn S; Pollrich K; Hertel J; Dittmar Y; Hommann M; Henklein P; Biskup C; Westermann M; Hollenberg MD; Settmacher U
    J Cell Physiol; 2007 Jun; 211(3):699-707. PubMed ID: 17323377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell death and hepatocarcinogenesis: Dysregulation of apoptosis signaling pathways.
    Schattenberg JM; Schuchmann M; Galle PR
    J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():213-9. PubMed ID: 21199533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic markers and putative therapeutic targets for hepatocellular carcinoma.
    Frau M; Biasi F; Feo F; Pascale RM
    Mol Aspects Med; 2010 Apr; 31(2):179-93. PubMed ID: 20176048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease.
    Calvisi DF; Pinna F; Ladu S; Pellegrino R; Muroni MR; Simile MM; Frau M; Tomasi ML; De Miglio MR; Seddaiu MA; Daino L; Sanna V; Feo F; Pascale RM
    Carcinogenesis; 2008 Aug; 29(8):1639-47. PubMed ID: 18579559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth factors as therapeutic targets in HCC.
    Furuse J
    Crit Rev Oncol Hematol; 2008 Jul; 67(1):8-15. PubMed ID: 18434184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Amphiregulin: a new growth factor in hepatocarcinogenesis.
    Berasain C; Castillo J; Perugorría MJ; Prieto J; Avila MA
    Cancer Lett; 2007 Aug; 254(1):30-41. PubMed ID: 17321672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of hepatocellular carcinoma and current treatment options.
    Raoul JL
    Semin Nucl Med; 2008 Mar; 38(2):S13-8. PubMed ID: 18243838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opportunities for targeted therapies in hepatocellular carcinoma.
    Thomas MB; Abbruzzese JL
    J Clin Oncol; 2005 Nov; 23(31):8093-108. PubMed ID: 16258107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.